Evidence map›Paper›PMID 34138966›Full record

ArticlePloS one2021

Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions.

Anna Goc, Waldemar Sumera, Matthias Rath, Aleksandra Niedzwiecki

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05134766 (Retrospective Evaluation of Clinical, Virological and Serological Data in Patients With Mild Acute Upper Respiratory Tract Infections), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05134766 completednot on this map

Retrospective Evaluation of Clinical, Virological and Serological Data in Patients With Mild Acute Upper Respiratory Tract Infections

TypeobservationalSponsorComplex Medical Centre Deli KlinikaRan2021 to 2021Enrolled380ConditionsAcute Upper Respiratory Tract InfectionArmsObservation only
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Natural products as a source of Coronavirus entry inhibitors.Frontiers in cellular and infection microbiology · 2024
    Review
  13. Effectiveness of TRIzol in Inactivating Animal Pathogens.Applied biosafety : journal of the American Biological Safety Association · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anna GocDepartment of Infectious Diseases, Dr. Rath Research Institute, San Jose, California, United States of America.ORCID 0000-0001-8736-2941
Waldemar SumeraDepartment of Infectious Diseases, Dr. Rath Research Institute, San Jose, California, United States of America.
Matthias RathDepartment of Infectious Diseases, Dr. Rath Research Institute, San Jose, California, United States of America.
Aleksandra NiedzwieckiDepartment of Infectious Diseases, Dr. Rath Research Institute, San Jose, California, United States of America.
Rath Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the pursuit of suitable and effective solutions to SARS-CoV-2 infection, we investigated the efficacy of several phenolic compounds in controlling key cellular mechanisms involved in its infectivity. The way the SARS-CoV-2 virus infects the cell is a complex process and comprises four main stages: attachment to the cognate receptor, cellular entry, replication and cellular egress. Since, this is a multi-part process, it creates many opportunities to develop effective interventions. Targeting binding of the virus to the host receptor in order to prevent its entry has been of particular interest. Here, we provide experimental evidence that, among 56 tested polyphenols, including plant extracts, brazilin, theaflavin-3,3'-digallate, and curcumin displayed the highest binding with the receptor-binding domain of spike protein, inhibiting viral attachment to the human angiotensin-converting enzyme 2 receptor, and thus cellular entry of pseudo-typed SARS-CoV-2 virions. Both, theaflavin-3,3'-digallate at 25 μg/ml and curcumin above 10 μg/ml concentration, showed binding with the angiotensin-converting enzyme 2 receptor reducing at the same time its activity in both cell-free and cell-based assays. Our study also demonstrates that brazilin and theaflavin-3,3'-digallate, and to a still greater extent, curcumin, decrease the activity of transmembrane serine protease 2 both in cell-free and cell-based assays. Similar pattern was observed with cathepsin L, although only theaflavin-3,3'-digallate showed a modest diminution of cathepsin L expression at protein level. Finally, each of these three compounds moderately increased endosomal/lysosomal pH. In conclusion, this study demonstrates pleiotropic anti-SARS-CoV-2 efficacy of specific polyphenols and their prospects for further scientific and clinical investigations.

Indexed as

A549 CellsAngiotensin-Converting Enzyme 2BenzopyransBiflavonoidsCatechinCell SurvivalCOVID-19CurcuminHumansPolyphenolsProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusVirionVirus AttachmentVirus InternalizationAngiotensin-Converting Enzyme 2BenzopyransBiflavonoidsbrazilinCatechinCurcuminPolyphenolsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2theaflavin-3,3'-digallate

Identifiers

PMID34138966
PMCPMC8211150
OpenAlexW3169688525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.